newsfilter
← Latest News
Business Wire·

Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview

- Second quarter total revenues of $264.6 million, up 9% year-over-year - Second quarter NUPLAZID® (pimavanserin) net product sales of $168.5 million, up 7% year-over-year - Second quarter DAYBUE®